Actelion Pharmaceuticals US

Actelion Pharmaceuticals US — A to Z Product Catalog

Marketed Products

• Opsumit® (macitentan)
  • Indication: Pulmonary arterial hypertension (PAH)
  • Dose/Form: Oral tablet, typically 10 mg once daily

• Opsynvi® (macitentan/tadalafil)
  • Indication: Pulmonary arterial hypertension (dual ERA + PDE-5 inhibitor therapy)
  • Dose/Form: Combination oral tablet; dosing per prescribing guidance

• Tracleer® (bosentan)
  • Indication: Pulmonary arterial hypertension
  • Dose/Form: Oral tablet, common adult dosing starts around 62.5 mg twice daily

• Uptravi® (selexipag)
  • Indication: Pulmonary arterial hypertension
  • Dose/Form: Oral tablet, initiation and titration per official protocol

• Ventavis® (iloprost)
  • Indication: PAH (NYHA Class III or IV)
  • Dose/Form: Inhalation solution—typically 6–9 inhalations per day

• Veletri® (epoprostenol for injection)
  • Indication: PAH in patients unresponsive to conventional therapy
  • Dose/Form: Continuous intravenous infusion; individualized dosing

• Zavesca® (miglustat)
  • Indication: Mild to moderate Type I Gaucher disease (when enzyme therapy unsuitable)
  • Dose/Form: Oral capsule, e.g., 100 mg three times per day

• Valchlor® (mechlorethamine gel)
  • Indication: Cutaneous T-cell lymphoma (mycosis fungoides, stages IA–IB)
  • Dose/Form: Topical gel 0.016%, applied once daily to lesions

Pipeline or Historical / Discontinued Programs

• Cadazolid
  • Indication: Clostridioides difficile–associated diarrhea (investigational)
  • Status: Development discontinued after Phase III

• (Other pipeline drugs)
  • Indications: Pediatric PAH, portopulmonary hypertension, and others currently under study
  • Dose/Form: Not yet defined; clinical-stage only

•